Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
AE

NASDAQ · AEON

AEON Biopharma, Inc.

Healthcare · Biotechnology

$0.33

Up+$0.04 (+12.72%)

Updated Sep 12, 2026, 2:41 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
13.25M
P/E ratio
-4,343.36
Dividend yield
0.00%
52-week range
$0.18 – $1.45
Volume
31.01M
Avg. volume
188.91K

Price performance

AEON price history

1M range · 20 trading sessions · Daily adjusted prices

AEON closed at $0.33 after 20 trading sessions, up 18.83% for the selected period.

Last close
$0.33
Period change
+18.83%
Period low
$0.19
Period high
$0.33
Daily close
View OHLC price history
AEON OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$0.298$0.3799$0.2903$0.326931.01M
Sep 10, 2026$0.296$0.3544$0.28$0.29203.62M
Sep 9, 2026$0.248$0.248$0.231$0.231473.87K
Sep 8, 2026$0.2451$0.2451$0.23$0.235157.21K
Sep 4, 2026$0.258$0.2759$0.24$0.2408758.72K
Sep 3, 2026$0.2785$0.2785$0.25$0.2547374.21K
Sep 2, 2026$0.2718$0.2801$0.268$0.271194.55K
Sep 1, 2026$0.2828$0.2867$0.2634$0.2766366.69K
Aug 31, 2026$0.3084$0.31$0.2859$0.2959507.91K
Aug 28, 2026$0.299$0.3157$0.28$0.31421.11M
Aug 27, 2026$0.2537$0.3142$0.2516$0.29394.7M
Aug 26, 2026$0.211$0.2531$0.211$0.25154.05M
Aug 25, 2026$0.2029$0.3296$0.19$0.211940.76M
Aug 24, 2026$0.201$0.2018$0.1899$0.1974956.85K
Aug 21, 2026$0.1916$0.2074$0.1797$0.19211.72M
Aug 20, 2026$0.205$0.2081$0.1772$0.19312.24M
Aug 19, 2026$0.2295$0.2593$0.1952$0.198424.33M
Aug 18, 2026$0.258$0.2638$0.245$0.245417.33K
Aug 17, 2026$0.2778$0.284$0.2555$0.2555489.37K
Aug 14, 2026$0.277$0.285$0.27$0.2751185.15K

Latest AEON news

The latest Smart Investors Daily articles mentioning AEON.

Stock researchCompany · Overview

AEON research

Overview

Company profile and research snapshot.

Company profile

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
AEON recent ratings
DateFirmRatingTarget
Aug 14, 2026HC Wainwright & Co.Buy—
Oct 8, 2025Aegis CapitalBuy—
Oct 1, 2024HC Wainwright & Co.Buy—
Aug 14, 2024HC Wainwright & Co.Buy—
Jul 10, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence supporting comparability and establish the basis for AEON’s planned multi-lot comparability study ALISO VIEJO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to

Yahoo · Aug 31, 2026

AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference

ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026

Yahoo · Aug 24, 2026

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By